RSNA 2009 

Abstract Archives of the RSNA, 2009


SSG08-03

Oral Manganese as Contrast Medium for MR Imaging Detection of Liver Metastases: A Phase II Clinical Study

Scientific Papers

Presented on December 1, 2009
Presented as part of SSG08: ISP: Gastrointestinal (Liver MR Imaging: Hepatobiliary Contrast Material Technique)

Participants

Helena Maria Dekker MD, Presenter: Nothing to Disclose
Jelle O. Barentsz MD, PhD, Abstract Co-Author: Nothing to Disclose
Yvonne Hoogeveen PhD, Abstract Co-Author: Nothing to Disclose

PURPOSE

evaluation of the safety and diagnostic performance of oral manganese as a contrast medium for MR-imaging detection of liver metastases.

METHOD AND MATERIALS

18 patients with known liver metastases were examined with MRI at 1.5T and 3T, before and 3 hours after oral administration of Mn-contrast diluted in 400 ml water. T1-weighted gradient echo sequences were obtained in coronal and in transversal planes. Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) of liver tissue and metastatic lesions was determined on the pre- and post-Mn contrast images. The number of detected liver metastases was evaluated. Pharmacokinetics was performed.  

RESULTS

The mean SNR of the liver improved after contrast administration at 1.5 T and 3T, with a factor 1.7. The mean CNR of the liver-to-metastases improved after contrast administration at 1.5 and 3T, with a factor 3.2 and 3.0, respectively. This significantly increased the number of metastases detected in the liver at both 1.5 T and 3T post contrast MR images. Blood samples showed that the Mn2+ concentration remained within the normal range in 14 patients. In 4 patients a temporary increase in plasma Mn2+ outside the normal range was seen 1 to 24 hours post dosing. In most patients the concentration of Mn2+ reached the highest level 3 hours post dosing. There were no contrast-related serious adverse events.  

CONCLUSION

oral Mn-contrast is a safe, simple and promising contrast agent, resulting in improved visualization of liver metastases by increase of SNR of the liver and CNR of the liver-to-metastases.

CLINICAL RELEVANCE/APPLICATION

oral manganese is a promising contrast agent for MR liver imaging

Cite This Abstract

Dekker, H, Barentsz, J, Hoogeveen, Y, Oral Manganese as Contrast Medium for MR Imaging Detection of Liver Metastases: A Phase II Clinical Study.  Radiological Society of North America 2009 Scientific Assembly and Annual Meeting, November 29 - December 4, 2009 ,Chicago IL. http://archive.rsna.org/2009/8005073.html